Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJodi J. LipofMCMatthew ClarkACAlfred Chung

Discussion

Loading...

Member takes

Overview

Prior BCMA-targeted therapy reduces CAR-T expansion and alters T cell phenotypes in patients with relapsed multiple myeloma, suggesting significant implications for treatment efficacy.

Key Points

  • Prior exposure to BCMA-targeted therapy significantly reduces CAR-T cell expansion in treated patients with relapsed myeloma.
  • Therapeutic efficacy indicators show reduced CD8+ T cell phenotypes in patients previously treated with BCMA therapies.
  • Analysis of cryopreserved peripheral blood mononuclear cells demonstrated variations in immune landscape post CAR-T therapy.
  • This study highlights the importance of understanding immune responses to improve treatment outcomes in relapsed multiple myeloma.

Cite This Study

Lipof et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1edhttps://doi.org/10.1182/blood-2025-3916
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition2025
  2. 2The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies2025
  3. 3Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies2025
  4. 4Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy2025 · 3 citations
  5. 5BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial2025 · 1 citations